Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement

Aug

19

Today In Oncology

Adding a Radiopharmaceutical to Standard Therapy in mRCC Does Not Improve Skeletal Events

Charles WM Roberts Named President and Chief Executive Officer of St. Jude Children’s Research Hospital

Is Excess Adiposity Linked to Vertebral Fracture Progression in Aromatase Inhibitor–Treated Early Breast Cancer?

Genomic Profiles and Adjuvant Chemotherapy Outcomes in Resected Pancreatic Cancer

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

Advertisement

© 2026 HSP News Service, L.L.C.